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Objectives: We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences
for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial.
Methods: Participants were randomly selected to receive either nevirapine at 200 mg twice daily (n¼256) or efavir-
enz at 600 mg daily (n¼270), both combined with two nucleoside analogues. Blood samples were drawn 12 h after
nevirapine or efavirenz administration, while on tuberculosis treatment and after tuberculosis treatment discontinu-
ation. In 62 participants, samples taken 12 h after drug administration were drawn weekly for the first month of ART.
Sixteen participants participated in an extensive pharmacokinetic study of nevirapine. Concentrations were com-
pared with the therapeutic ranges of 3000–8000 ng/mL for nevirapine and 1000–4000 ng/mL for efavirenz.
Results:Nevirapine concentrations at the end of the first week of treatment (on antituberculosis drugs) did not differ
from concentrations off tuberculosis treatment, but declined thereafter. Concentrations at steady-state were
4111 ng/mL at week 12 versus 6095 ng/mL at week 48 (P,0.0001). Nevirapine concentrations ,3000 ng/mL
were found to be a risk factor for virological failure. Efavirenz concentrations were higher on than off tuberculosis
treatment (2700 versus 2450 ng/mL, P,0.0001).
Conclusions: The omission of the 2 week lead-in dose of nevirapine prevented low concentrations at treatment ini-
tiation but did not prevent the risk of virological failure. Results support the WHO recommendation to use efavirenz at
600 mg daily in patients on rifampicin-based antituberculosis therapy.
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Introduction
Tuberculosis is a leading opportunistic infection and a major
cause of mortality among individuals infected with HIV.
Substantial reduction of tuberculosis-related morbidity and mor-
tality among individuals with HIV can be achieved with early initi-
ation of ART.1 – 3 Efavirenz is an NNRTI drug recommended by the
WHO as a first-line ART for individuals coinfected with HIV and
tuberculosis.4 Nevirapine has been widely used in resource-limited
countries with a high burden of HIV due to the convenience and
affordability of generic fixed-dose combinations.
Nevirapine could be an alternative NNRTI for HIV/tuberculosis-
infected individuals and may be preferred to efavirenz in some
cases where efavirenz presents CNS toxicity that requires discon-
tinuation of early treatment.5 However, nevirapine has other risks,
and studies have found that clearance of nevirapine is more sen-
sitive than efavirenz to the potent enzyme induction caused by
rifampicin; as a result nevirapine-based regimens carry greater
risk of sub-therapeutic NNRTI concentrations.6 – 8 This is related
to differences in their biotransformation pathways, as nevirapine
is metabolized by several P450 cytochromes (CYPs) (CYP2B6,
CYP3A and CYP2C) and efavirenz is metabolized mainly by
CYP2B6.9,10 Reduction in nevirapine levels when combined with
rifampicin-based antituberculosis therapy is more pronounced
during the first 2 weeks of ART, when nevirapine is typically pre-
scribed at half dose (200 mg) (lead-in dose) as a way of
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preventing hypersensitivity.11 There is debate over the optimal
dose of efavirenz when combined with rifampicin-based antitu-
berculosis therapy.12 Therefore, the best dose regimen of both
NNRTIs remains a subject of discussion.
The ANRS 12146-CARINEMO trial was a multicentre, open-label,
randomized, non-inferiority clinical trial conducted at three health-
centres in Maputo. It was the first trial conducted in Mozambique,
Africa, comparing the efficacy and safety of nevirapine and efavir-
enz ARTs in HIV/tuberculosis-coinfected patients. In patients who
were on antituberculosis therapy, nevirapine was initiated at the
full dose of 200 mg twice daily and efavirenz at 600 mg daily.
Although the non-inferiority of the nevirapine regimen was not
shown, the results led investigators to conclude that nevirapine
at full dose could be a safe alternative for patients unable to toler-
ate efavirenz.13 The present analysis used data from the ANRS
12146-CARINEMO trial to describe nevirapine and efavirenz plasma
concentrations during and after rifampicin-based tuberculosis
treatment from early treatment initiation to the end of the first
year of ART and to analyse whether these concentrations could
be related to virological failure or the occurrence of side effects.
Methods
Study design and participants
Study design, eligibility criteria and study procedures for the ANRS
12146-CARINEMO trial are described elsewhere.13 The research was
conducted in accordance with the Declaration of Helsinki and national
and institutional standards. The research protocol was approved by
two ethics committees: the Comite´ Nacional de Bioe´tica para a Sau´de,
Mozambique (228/CNBS/2007), and the Me´decins Sans Frontie`res Ethics
Review Board, Zurich, Switzerland (approval letter dated 2 May 2007). All
participants provided a signed informed consent form. In brief, 573
HIV/tuberculosis-coinfected patients were enrolled 4 –6 weeks after
initiation of tuberculosis treatment to receive either nevirapine
(200 mg twice daily) without a lead-in dose or efavirenz (600 mg once
daily). All participants received stavudine (30 mg twice daily) and lamiv-
udine (150 mg twice daily), and once-daily tuberculosis treatment
consisting of an initial 2 month intensive phase of fixed-dose combin-
ation treatment containing 150 mg of rifampicin, 75 mg of isoniazid,
275 mg of ethambutol and 400 mg of pyrazinamide, followed by a
4 month maintenance phase of fixed-dose combination treatment con-
taining rifampicin and isoniazid. Dosage was adjusted based on body weight
in both the intensive and maintenance phases: rifampicin (10 mg/kg), isoni-
azid (5 mg/kg), ethambutol (15 mg/kg) and pyrazinamide (25 mg/kg).
Clinical examination and laboratory analysis were performed at enrol-
ment, on a weekly basis during the first 8 weeks and every 4 weeks there-
after until study completion at 48 weeks. CD4+ Tcell counts were obtained
at screening and at weeks 24 and 48. HIV-1 RNA was determined in plasma
(limit of quantification 50 copies/mL) at enrolment and at weeks 12, 24, 36
and 48. Adverse events were coded according to MedDRA and graded
according to the ANRS scale (www.anrs.fr) as previously described.13
Pharmacokinetic studies
Pre-dose concentrations of nevirapine and morning concentrations 12 h
after evening intake (C12) of efavirenz were measured at week 12 (while
participants were on tuberculosis drugs) and at weeks 36 and 48 (when
participants were off tuberculosis drugs). C12 was measured at the
end of week 2 of ART to monitor drug exposure in the first 100 participants
enrolled in the nevirapine treatment arm. A sub-group of participants were
selected to be in the early sample group for additional blood samples
drawn on days 7 (week 1), 14 (week 2), 21 (week 3) and 28 (week 4) of
ART to assess nevirapine and efavirenz concentrations.
An additional sub-group of participants being treated with nevirapine
were selected to be in a pharmacokinetic study group. They participated in
an extensive nevirapine pharmacokinetic study and had blood samples
collected during a dosing interval at steady-state 4 weeks after initiation
of ART (while on antituberculosis drugs) and 4 weeks after completion of
antituberculosis treatment (while off antituberculosis drugs). Blood was
drawn before drug intake (time 0) and after drug intake (0.5, 1, 1.5, 2, 4,
6, 8, 10 and 12 h). Plasma concentrations of nevirapine and efavirenz were
assayed by validated HPLC methods with a lower limit of quantification
(LLOQ) of 25 and 50 ng/mL, respectively.14,15 Plasma concentrations
were compared with previously described therapeutic ranges, which are
between 3000 and 8000 ng/mL for nevirapine16 and between 1000 and
4000 ng/mL for efavirenz.17
A non-compartmental method was used to estimate nevirapine phar-
macokinetic parameters (WinNonlin software, Pharsight Corporation,
Mountain View, CA, USA). Plasma Cmax, time to plasma peak concentration
(Tmax) and plasma Cmin were the observed values. The AUC during the 12 h
dosing intervals at steady-state (AUC0 – 12) was estimated using the linear
up–log down trapezoidal method. Two-sided 90% CIs were constructed
for the ratios of the geometric mean values (GMR parameters) with versus
without tuberculosis treatment of AUC0 – 12, Cmin and Cmax.
Statistical analysis
Unless otherwise indicated, descriptive data were reported using the
median and IQR. Nevirapine or efavirenz plasma concentrations were
excluded from analysis in the following cases: treatment switch in patients
with adverse event or pregnancy; patients still on antituberculosis drugs at
weeks 36 and 48; and blood samples collected outside the range of 11.5–
15.5 h after the last drug intake. Concentrations below the LLOQ were
included as LLOQ/2 for analysis. As normality of drug concentrations
was not achieved after log transformation, plasma concentrations of
NNRTIs on and off antituberculosis therapy were compared by the
Wilcoxon signed-rank test. Mixed models were used to analyse the change
in log-transformed concentrations, with time being a fixed effect in the
model. Logistic regression was used to identify predictors of virological fail-
ure (HIV1 RNA ≥50 copies/mL) at week 48 and binary safety outcomes of
interest (occurrence of central neurological adverse event and hepatitis
grade 2 or higher). Factors with an association with a P value ,0.2 were
used for multivariate analyses.
A sensitivity analysis was performed for predictors of virological failure
after excluding NNRTI plasma concentration below the LLOQ used as a sur-
rogate marker of poor treatment adherence. All statistical analyses were
conducted with StataSETM software (2005, Release 12.1; StataCorp,




Of 573 patients enrolled in the ANRS 12146-CARINEMO trial, 526
had at least one 12 h (13.5+2 h) post-dose concentration
measurement available for nevirapine or efavirenz at weeks
12, 36 and 48 of study follow-up. One hundred and fourteen par-
ticipants on nevirapine had an available concentration measure
at week 2. Sixty-two patients were enrolled in the nevirapine and
efavirenz early sample group. Sixteen patients (eight males) par-
ticipated in the two periods of the extensive nevirapine pharma-
cokinetic study. Baseline characteristics of these patients are
shown in Table 1. Participant age and weight at enrolment
were 33 years and 52.1 kg, and 57% were male. CD4+ T cell
count was 92/mm3 and HIV-1 RNA was 5.6 log10 copies/mL.
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The baseline characteristics of participants in each subgroup
were similar to the characteristics of all participants.
Nevirapine and efavirenz exposure at treatment initiation
(early sample group)
Thirty-two patients were on nevirapine and 30 patients were on
efavirenz. During co-administration, nevirapine concentrations
decreased over time from week 1 (5721 ng/mL) to week 12
(4003 ng/mL) (P¼0.001) and increased after completion of
antituberculosis therapy (6271 ng/mL) (P,0.001) (Figure 1).
Nevirapine concentrations remained steady from week 3
(3844 ng/mL) to week 12 when combined with antituberculosis
therapy. Conversely, there was a non-significant increase in
efavirenz concentration from week 1 (2509 ng/mL) to week 3
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Figure 1. Plasma trough concentrations 12 h after dosing (C12) of nevirapine in 32 patients and efavirenz in 30 patients during 48 weeks of ART. The
white horizontal line shows the median; IQRs are shown by boxes; the whiskers show minimum and maximum without outliers; outliers are indicated by
circles. Dotted lines are the lower targets of the therapeutic ranges (3000 and 1000 ng/mL for nevirapine and efavirenz, respectively). EFV, efavirenz; NVP,
nevirapine; ARV, antiretroviral; TB, tuberculosis.
Table 1. Demographic, clinical and laboratory characteristics of patients at baselinea
Characteristic
Entire study populationb Early samples group
Extensive PK group
NVP group (n¼256) EFV group (n¼270) NVP group (n¼32) EFV group (n¼30) NVP group (n¼16)
Age, years 33 (29–41) 33 (28–40) 36 (31–42) 34 (29–38) 36 (31–47)
Sex, male 142 (55.5) 160 (59.3) 20 (62.5) 17 (56.7) 8/16 (50.0)
Weight, kg 52.0 (46.6–57.5) 52.3 (47.2–58.7) 51.9 (46.0–58.9) 50.9 (47.2–55.1) 52.6 (46.6–55.6)
BMI, kg/m2 18.7 (17.2–20.3) 18.9 (17.6–20.3) 19.1 (16.9–20.4) 18.5 (16.9–20.1) 18.3 (17.0–19.5)
Haemoglobin, g/dL 9.4 (8.5–10.3) 9.4 (8.3–10.4) 9.0 (8.1–9.8) 9.4 (8.3–10.4) 9.4 (7.9–10.3)
ALT, IU/L 22.6 (14.7–36.8) 23.0 (15.6–37.7) 26.4 (12.8–44.4) 28.7 (22.1–38.3) 13.0 (9.0–20.0)
Total bilirubin, mg/dL 0.4 (0.3–0.6) 0.5 (0.3–0.6) 0.4 (0.3–0.5) 0.5 (0.3–0.7) 0.8 (0.7–0.9)
CD4+ T cell count, cells/mm3 94 (44–152) 86 (44–144) 106 (47–153) 91 (69–127) 86 (57–169)
HIV-1 RNA, log10 copies/mL 5.7 (5.1–6.0) 5.5 (5.2–6.1) 5.7 (5.3–5.9) 5.4 (5.2–6.0) 5.5 (5.2–5.7)
HBsAg, reactive 53/255 (20.8) 57/266 (21.4) 1/32 (3.1) 4/30 (13.3) 1 (6.3)
HCV antibody, reactive 4 (1.6) 5 (1.9) 1 (3.1) 1 (3.3) 1 (6.3)
Pulmonary tuberculosis 202 (78.9) 203 (75.2) 29 (90.6) 20 (66.7) 11 (68.8)
Smear-positive pulmonary tuberculosis 93/202 (46.0) 111/203 (54.7) 7/29 (24.1) 16/20 (80.0) 9/11 (81.8)
NVP, nevirapine; EFV, efavirenz; HCV, hepatitis C virus; PK, pharmacokinetic.
aData are median (IQR), n (%) or n/N (%).
bAt least one 12 h post-dosing concentration available for nevirapine or efavirenz at weeks 12, 36 and 48 of study follow-up.
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decrease after antituberculosis therapy discontinuation at week
48 (2329 ng/mL) when compared with week 12 (P,0.001).
Importantly, when nevirapine was initiated at full dose, plasma
concentrations 1 week after starting nevirapine during co-
administration with antituberculosis therapy were not signifi-
cantly different from those after completion of antituberculosis
therapy at week 48. Similar findings were obtained with efavirenz.
Nevirapine and efavirenz exposure on and off
antituberculosis therapy
Concentrations on and off antituberculosis therapy in the whole
population are presented in Table 2. Nevirapine and efavirenz con-
centrations were not different when measured at weeks 36 and
48 after tuberculosis therapy discontinuation, and concentrations
at week 48 were therefore considered for further comparisons.
Nevirapine plasma concentrations at weeks 2 and 12 were signifi-
cantly lower than at week 48 (P¼0.0003 and P,0.0001, respect-
ively). Importantly, 22% and 25% of patients had concentrations
,3000 ng/mL at weeks 2 and 12 versus 11% at week 48. In the
16 patients who participated in the extensive nevirapine pharma-
cokinetic study, nevirapine concentrations were lower while on
antituberculosis drugs than after discontinuation of antitubercu-
losis drugs (Figure S1, available as Supplementary data at JAC
Online). Nevirapine AUC0 – 12 and Cmin were reduced by 13% and
17% respectively, but the 90% CIs of GMR parameters failed to
lie within the 0.80– 1.25 bioequivalence range, as indicated
in Table 3. Efavirenz concentrations decreased slightly but signifi-
cantly after tuberculosis drug discontinuation between weeks 12
and 48 (P,0.0001). Efavirenz concentrations were,1000 ng/mL
in 9% of participants at weeks 12 and 48. At week 12, 5.1% of
the patients had efavirenz concentrations ,50 ng/mL (limit of
detection) and were possibly not fully adherent, and only 3.8%
had concentrations ≥50 and ,1000 ng/mL. Notably, 25% of
the participants had concentrations of efavirenz and nevirapine
above the therapeutic range when off antituberculosis drugs,
and the proportion was as high as 37% when efavirenz was com-
bined with antituberculosis drugs.
Concentration–efficacy relationship
Plasma HIV-1 RNA was ,50 copies/mL at weeks 12, 24 and 48 in
77.2% (156/202), 78.3% (155/198) and 77.3% (157/203) of the
participants on nevirapine and 85.0% (170/200), 85.5% (171/
200) and 88.2% (164/186) of the participants on efavirenz,
respectively. Analysis within each treatment arm demonstrated
that, in the nevirapine arm, having reactive hepatitis B surface
antigen (HBsAg), being a male and having C12 ,3000 ng/mL at
week 12 were independently associated with the risk of virological
failure, as shown in Table 4. Interestingly, such association was
unchanged when concentrations below the LLOQ were removed.
The only predictor of virological failure in the efavirenz arm was
having concentrations ,1000 ng/mL at week 12 (Table 4). The
association was no longer significant after excluding concentra-
tions below the LLOQ.
Safety issues related to concentrations
Fourteen participants on nevirapine and two participants on efa-
virenz switched treatment because of adverse events. There were
11 cases of hepatitis (for 7 participants concentrations ranged
Table 2. Concentrations of nevirapine and efavirenz at weeks 2 and 12 (on tuberculosis drugs) and at weeks 36 and 48 (off tuberculosis drugs) measured
12 h after dosing (trough concentrations for nevirapine and mid-dose concentrations for efavirenz)
Time (weeks)
2 12 36 48
Nevirapine
no. of patients 114 225 218 205
plasma concentration, ng/mL
median (IQR) 4759 (3201–7327) 4111 (2970–5534) 5970 (4261–7898) 6095 (4521–8504)*,**
trough
,25 3 (2.6) 6 (2.7) 6 (2.8) 3 (1.5)
≥25 to ,3000 22 (19.3) 51 (22.7) 15 (6.9) 20 (9.8)
≥3000 to ,8000 68 (59.6) 148 (65.8) 144 (66.1) 125 (61.0)
≥8000 21 (18.4) 20 (8.9) 53 (24.3) 57 (27.8)
Efavirenz
no. of patients — 235 199 189
plasma concentration, ng/mL
median (IQR) — 2700 (1701–6965) 2604 (1742–4412) 2450 (1742–4086)**
trough
,50 — 12 (5.1) 6 (3.0) 5 (2.6)
≥50 to ,1000 — 9 (3.8) 9 (4.5) 12 (6.3)
≥1000 to ,4000 — 127 (54.0) 131 (65.8) 122 (64.6)
≥4000 — 87 (37.0) 53 (26.6) 50 (26.5)
*Week 2 versus week 48, P¼0.0003.
**Week 12 versus week 48, P,0.0001.
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from 3417 to 30321 ng/mL) and 3 of rashes (concentrations not
available) in the nevirapine arm and two acute psychiatric disor-
ders in the efavirenz arm (786 and 5863 ng/mL). There was no sig-
nificant association between the occurrence of grade 2 or higher
CNS adverse events reported within the first 12 weeks of ART in
six participants on efavirenz and efavirenz concentrations
.4000 ng/mL at week 12 (P¼0.293). Among the factors analysed
for association with the occurrence of hepatitis (increase in ALT) of
grade 2 or higher, which occurred in 32 patients, only efavirenz
concentration during the same time period (OR 5.25, 95% CI
2.1–13.2, P¼0.0002) was significant.
Discussion
In this study we describe nevirapine and efavirenz exposure from
initiation of ART in patients coinfected with HIV and tuberculosis
on antituberculosis therapy until 6 months after completion
of antituberculosis treatment in a large cohort of participants.
We have demonstrated marked differences in exposure to
two NNRTIs when combined with rifampicin/isoniazid-based anti-
tuberculosis therapy in an African population. Metabolism of
nevirapine, but not of efavirenz, is induced by this concomitant
treatment. However, plasma concentrations of both nevirapine
(omitting the lead-in dose) and efavirenz at the end of the first
week of ART were in the same range as they were after discontinu-
ation of antituberculosis drugs, which is of importance for optimal
antiretroviral efficacy at ART initiation. Nevirapine concentrations
declined thereafter, reaching a steady-state from week 3 to the
end of antituberculosis therapy. Our extensive pharmacokinetic
study supports these pre-dose concentration findings. Despite
such a moderate decrease, 25% of the participants on nevirapine-
based ART had concentrations ,3000 ng/mL on antituberculosis
therapy (week 12) versus 11% after antituberculosis therapy dis-
continuation. Such a decrease was a predictor of virological failure.
Nevirapine concentrations reported here differ from those in
previous studies, in which all participants received the standard
lead-in dose and as many as 59%–79% of HIV/tuberculosis-
coinfected patients had low pre-dose concentrations during the
first 2 weeks of rifampicin-based antituberculosis therapy.18,19
Our results support our study design, in which a full dose of nevir-
apine was given at initiation of treatment to avoid the first 2 week
period of treatment with low nevirapine concentrations.
Concentrations measured at the end of the first 2 weeks of nevir-
apine treatment at 200 mg twice daily were slightly lower
Table 3. Nevirapine pharmacokinetic parameters (16 patients in the nevirapine treatment group)a
Time Cmin (ng/mL) Cmax (ng/mL) Tmax (h) AUC0 – 12 (ng.h/mL)
With antituberculosis drugs 4513 (2527–8797) 6561 (4744–10311) 2.0 (1.5–4.2) 66743 (46817–114072)
Alone 5025 (3557–10662) 7283 (5246–13637) 1.5 (1.0–4.0) 71332 (53440–146908)
GMRb (90% CI) 0.83 (0.71–0.97) 0.89 (0.79–1.00) 0.87 (0.77–0.99)
aData are expressed as median (range).
bRatio of geometric means for parameters with rifampicin to those without rifampicin.
Table 4. Factors associated with virological failure after 48 weeks of ART among participants in the nevirapine and efavirenz treatment groups
Possible risk factors
Treatment outcome at week 48,
proportion of patients (%) Univariate analysis Multivariate analysis
success failure OR (95% CI) P value OR (95% CI) P value
Nevirapine
C12 ,3000 ng/mL at week 12 30/156 (19.2) 20/46 (43.5) 3.23 (1.59–6.54) 0.001 3.44 (1.65–7.17) 0.001
male 87/175 (49.7) 37/53 (69.8) 2.34 (1.21–4.51) 0.011 2.18 (1.03–4.61) 0.036
weight ≤50 kg 70/175 (40.0) 20/53 (37.7) 0.92 (0.95–3.29) 0.767 — —
HBsAg, reactive 33/175 (18.9) 15/53 (28.3) 1.69 (0.83–3.42) 0.148 2.51 (1.15–5.51) 0.035
baseline CD4+ cell count ,50 cells/mm3 48/175 (27.4) 13/53 (24.5) 0.86 (0.42–1.75) 0.674 — —
HIV-1 RNA viral load at baseline ≥5.5 log 77/175 (44.0) 17/53 (32.1) 1.66 (0.87–3.19) 0.118 — NS
Efavirenz
C12 ,1000 ng/mL at week 12 7/170 (4.1) 5/30 (16.7) 4.70 (1.37–15.81) 0.020 4.70 (1.37–15.81) 0.020
male 109/198 (55.1) 18/33 (54.6) 0.98 (0.47–2.05) 0.957 — —
weight ≤50 kg 77/198 (38.9) 21/33 (63.6) 0.90 (0.42–1.93) 0.782 — —
HBsAg, reactive 46/198 (23.2) 4/33 (12.1) 0.44 (0.15–1.33) 0.116 — NS
baseline CD4+ cell count ,50 cells/mm3 51/198 (25.8) 12/33 (36.4) 1.65 (0.76–3.58) 0.216 — —
HIV-1 RNA viral load at baseline ≥5.5 log 101/198 (51.0) 11/33 (33.3) 2.08 (0.96–4.52) 0.058 — NS
NS, not significant.
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(4759 ng/mL) than that reported in the study of Avihingsanon
et al.18 (5300 ng/mL), in which 16 Thai patients included in the
600 mg nevirapine daily dose group received a lead-in dose of
200 mg twice daily, but higher than that reported by Lamorde
et al.20 in 9 Ugandan adults (2920 ng/mL). Those two studies
are limited by the small number of patients included and the
absence of a relationship with virological response. The study con-
ducted in Thai patients was prematurely discontinued because
the lead-in strategy with nevirapine at 200 mg twice daily was
associated with a high rate of nevirapine hypersensitivity.18 In
our study, treatment tolerance was good and did not differ
between the nevirapine and efavirenz groups.13 The nevirapine
concentrations that we observed at steady-state of induction
were similar to those reported in one study conducted in
Africa21 but lower than those in other studies conducted in differ-
ent countries.19,22 Differences in patients’ weight and pharmaco-
genetics could explain the differences in nevirapine exposure
between African and South-East Asian populations. This decrease
in nevirapine concentrations is surprising as it is generally accepted
that the enzyme induction process is maximal after 10–15 days of
drug-inducer administration. Nevirapine metabolism involves dif-
ferent CYP enzymes, which may be induced differently by rifampicin
and nevirapine. Interestingly, the autoinduction process of efavir-
enz was demonstrated to continue up to 16 weeks of therapy;
whether such a mechanism could occur for nevirapine combined
with rifampicin remains to be investigated.23
Recent studies, mainly conducted in sub-Saharan Africa,
showed that, at least in some sub-groups of patients, efavirenz
concentrations were higher on than off antituberculosis
therapy.24,25 Bertrand et al.26 recently demonstrated that the
efavirenz–antituberculosis drug interaction depends on CYP2B6
and NAT2 genetic polymorphism, suggesting that isoniazid,
which has inhibiting properties with respect to some non-
CYP2B6 biotransformation pathways, could play a role, counter-
balancing the inducing properties of rifampicin. There was no
significant association between the occurrence of grade 2 or
higher CNS adverse events reported within the first 12 weeks of
ART in six participants on efavirenz and efavirenz concentrations
.4000 ng/mL at week 12 (P¼0.293). Among the factors analysed
for association with the occurrence of hepatitis (increase in ALT) of
grade 2 or higher, which occurred in 32 patients, only efavirenz
concentration .4000 ng/mL during the same time period (OR
5.25, 95% CI 2.1–13.2, P¼0.0002) was significant.
Importantly, the association between low nevirapine concen-
trations at week 12 and virological failure at 48 weeks was not
affected by the exclusion of concentrations below the LLOQ
(used as surrogate marker of poor adherence) from the analysis,
which was not the case for efavirenz. This finding supports the
main results of the CARINEMO trial, which failed to show the non-
inferiority of nevirapine compared with efavirenz, and demon-
strates the different drug–drug interaction mechanism, which
explains, at least in part, the difference in virological response
between the two antiretroviral regimens.13
Liver injury due to drug usage was reported in African patients
with high efavirenz concentrations when efavirenz was combined
with antituberculosis therapy.27,28 In contrast to some studies,17,29
other studies and our study failed to correlate the few recorded CNS
adverse effects with high efavirenz concentrations.25
Our study had some limitations. First, C12 and not pre-dose
trough concentrations were collected as a surrogate of efavirenz
exposure. However, such approximation is acceptable as efavirenz
has an elimination half-life longer than the 24 h dosing interval,
which would minimize fluctuations between peak and trough
concentrations.30 Second, it is now well demonstrated that nevir-
apine and efavirenz concentrations are highly dependent on
CYP2B6 genetic polymorphism.6,31 – 35 Indeed, the frequency of
the CYP2B6 loss-of-function variants was reported to be higher
in people of African than in those of European descent.6,26,32,33
The frequency of the CYP2B6516T loss-of-function allele in the
Mozambican population is as high as 40%36 and explains, at
least in part, the high concentrations observed in our study. The
exact mechanism of the nevirapine–antituberculosis drug inter-
action warrants further study, and pharmacogenetics could be
a useful tool. Third, none of the metabolites of nevirapine or efa-
virenz was quantified. Several nevirapine metabolites involving
different CYP pathways were identified. 8-Hydroxy efavirenz is
the main CYP2B6-mediated metabolite of efavirenz. Metabolite
concentrations in plasma were found to be below those of the
parent drug and therefore their contribution to nevirapine or efa-
virenz efficacy is unlikely.23,37
In conclusion, this pharmacokinetic study conducted in 526
HIV/tuberculosis-coinfected patients adds new evidence on nevir-
apine or efavirenz exposure and drug –drug interaction when
combined with rifampicin- and isoniazid-based antituberculosis
treatments. Our efavirenz data are in agreement with most recent
studies and support the WHO recommendation. Omitting the
200 mg once daily dosage for the first 2 weeks of nevirapine treat-
ment allows concentrations to be within the therapeutic range at
initiation of treatment when combined with antituberculosis
drugs, and this drug regimen was well tolerated. However, such
a strategy does not avoid a decrease in nevirapine concentrations
after the first 2 weeks of treatment and supports the results of the
main trial, which recommends using efavirenz whenever possible.
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